Diagnosing membranoproliferative glomerulonephritis requires careful examination and specialized testing to identify inflammation in the kidney’s filtering units and determine the underlying cause of this uncommon disease.

Understanding When to Seek Diagnostic Testing

People who should consider undergoing diagnostic testing for membranoproliferative glomerulonephritis, or MPGN, typically first notice changes in their urine or experience swelling in their body. This kidney disorder primarily affects children and young adults, though it can occur at any age. Children between ages 2 and 15 are particularly vulnerable to the primary forms of this disease, while secondary forms tend to affect adults over age 30.^[1][2]

It’s advisable to seek medical evaluation if you notice blood in your urine, which may appear dark, smoky, cola-colored, or tea-colored. Cloudy urine or a noticeable decrease in the amount of urine you produce are also warning signs. Many people first become concerned when they develop swelling, particularly in the legs and ankles, though it can affect any part of the body. This swelling happens because the damaged kidneys leak protein into the urine, causing fluid to escape from blood vessels into body tissues.^[1]

Some individuals experience changes in mental status, such as decreased alertness or concentration, which occur when nitrogen waste products build up in the blood. High blood pressure is another common finding that may prompt further investigation. Importantly, not everyone with MPGN has obvious symptoms. Some people discover they have the condition only when routine urine tests reveal abnormalities, such as protein or blood in the urine.^[1][5]

Classic Diagnostic Methods for MPGN

Diagnosing membranoproliferative glomerulonephritis involves multiple layers of testing because the condition affects how the kidney’s tiny filters, called glomeruli, work. Your healthcare provider begins with a physical examination to look for signs of excess fluid in your body. They will check for swelling, listen to your heart and lungs with a stethoscope for abnormal sounds, and measure your blood pressure, which is often elevated in people with MPGN.^[1]

Blood Tests

Blood tests are essential for evaluating kidney function and identifying specific patterns that point toward MPGN. A BUN (blood urea nitrogen) and creatinine blood test measures waste products that the kidneys normally filter out. When these levels are elevated, it signals that the kidneys aren’t working as they should. The serum creatinine level may be normal in early stages or elevated if kidney function has already declined.^[1][5]

One of the most distinctive features of MPGN is low levels of certain proteins in the blood called complement. Blood complement levels are tested because hypocomplementemia, or low complement, is present in approximately 75 percent of people with this condition. The specific pattern of complement abnormality helps doctors classify the type of MPGN. In immunoglobulin or immune complex-mediated MPGN, the classic complement pathway is activated, so C3 is normal or mildly decreased while C4 is typically decreased. In complement-mediated MPGN, the alternate complement pathway is activated, meaning C3 is decreased but C4 is normal.^[2][5]

A complete blood count is often obtained during the diagnostic process to check for anemia or other blood abnormalities. Additional specialized blood tests help identify underlying causes. For example, tests for hepatitis B and C viruses are important because chronic viral infections can trigger secondary MPGN. Testing for autoimmune diseases like lupus, screening for certain cancers, and checking for abnormal antibodies all help determine whether the MPGN is primary (occurring on its own) or secondary (caused by another condition).^[4][5]

More recently, a blood test for phospholipase A2 receptor antibodies, sometimes called anti-PLA2R antibodies, has been developed. Although this test is more commonly associated with another kidney condition called membranous nephropathy, understanding antibody patterns helps doctors distinguish between different types of kidney disease.^[16]

Urine Tests

Urinalysis is a simple but powerful diagnostic tool that examines the content of your urine. In MPGN, the urine sediment typically reveals hematuria, which means red blood cells are present in the urine. Under a microscope, these red blood cells often appear dysmorphic, meaning they have an abnormal shape, and red cell casts may be seen. These casts are cylindrical structures formed in the kidney’s tubules and are a sign of kidney inflammation.^[5]

Proteinuria, or protein in the urine, is another hallmark finding. The amount of protein leaking into the urine varies considerably from person to person. Some have only mild proteinuria, while others have nephrotic-range proteinuria, which means more than 3 grams of protein are lost in 24 hours. When protein levels are this high, people often develop nephrotic syndrome, a condition characterized by low protein levels in the blood, high cholesterol, and significant swelling throughout the body. A 24-hour urine collection or a spot urine protein-to-creatinine ratio helps quantify exactly how much protein is being lost.^[1][5]

Kidney Biopsy

The definitive diagnosis of MPGN requires a kidney biopsy. This procedure involves taking a small sample of kidney tissue, usually using a needle inserted through the skin under local anesthesia. The tissue sample is then examined under various types of microscopes to identify specific patterns of damage and deposits.^[5]

Under a light microscope, MPGN shows three characteristic features: proliferation of mesangial and endothelial cells along with expansion of the mesangial matrix; thickening of the peripheral capillary walls; and a distinctive pattern where the capillary wall appears to have a double contour, often described as a “tram-track” appearance. This happens because mesangial cells position themselves between the endothelial cells and the basement membrane.^[2][4]

Immunofluorescence microscopy looks at how antibodies and complement proteins are deposited in the kidney tissue. This is crucial for classifying MPGN into its different types. The preferred modern classification divides MPGN based on what is deposited: immunoglobulin/immune complex-mediated MPGN shows deposits of both immunoglobulins and complement; complement-mediated MPGN shows mainly complement C3 deposits with little or no immunoglobulin; and MPGN without immunoglobulin or complement deposition shows neither.^[4][5]

Electron microscopy provides even more detailed information by revealing where dense deposits are located. Historically, doctors used electron microscopy findings to classify MPGN into types I, II, and III based on deposit location. Type I shows subendothelial deposits, type II (also called dense deposit disease) shows extremely dense material throughout the basement membrane, and type III shows both subepithelial and subendothelial deposits. However, current classification focuses more on the immunofluorescence pattern and the disease mechanism rather than just the location of deposits.^[5][6]

Additional Diagnostic Tests

Once MPGN is diagnosed, doctors perform additional tests to search for underlying causes, since the majority of cases are secondary to another condition. These investigations might include chest X-rays to check for infections or tumors, liver function tests if hepatitis is suspected, and various screening tests for autoimmune diseases. In some cases, doctors may look for abnormal proteins in the blood or urine that suggest conditions like multiple myeloma or other plasma cell disorders.^[4][6]

For patients with dense deposit disease, a subtype of complement-mediated MPGN, eye examinations are important. These individuals have a higher incidence of eye abnormalities, including drusen (deposits in the retina), retinal pigment changes, and vision problems. Early detection of these changes allows for monitoring and potential intervention to preserve vision.^[5]

Diagnostics for Clinical Trial Qualification

When patients with MPGN are considered for enrollment in clinical trials, they typically undergo a comprehensive set of diagnostic tests to establish their eligibility. Clinical trials investigating new treatments for MPGN require careful documentation of disease severity, kidney function, and the specific type of MPGN present.^[7]

Kidney biopsy results are fundamental for trial entry. Most studies require confirmation of MPGN by biopsy and classification based on immunofluorescence findings. The pattern of deposits—whether immunoglobulin-mediated, complement-mediated, or without deposits—determines which clinical trial might be appropriate. Some trials specifically target complement-mediated disease, for instance, because the mechanism of injury differs from immune complex-mediated forms.^[5][7]

Baseline kidney function assessment is essential. Trials typically use the estimated glomerular filtration rate (eGFR) to measure how well the kidneys are filtering blood. This calculation, based on serum creatinine, age, gender, and sometimes race, provides a standardized way to stage kidney disease. Some trials only accept patients with eGFR above or below certain thresholds. For example, patients with very advanced kidney disease (eGFR below 30 mL/min/1.73 m²) may be excluded from some trials because their kidneys are too damaged to show meaningful response to experimental treatments.^[7][14]

Proteinuria measurement is another standard criterion. Many trials require that patients have proteinuria exceeding 3 grams per day or nephrotic-range proteinuria to be eligible. This ensures that enrolled patients have active disease that might respond to treatment. Serial measurements of proteinuria during the trial help researchers determine whether the experimental treatment is reducing protein leakage.^[7][14]

Complement testing serves as both an entry criterion and a monitoring tool in trials. Researchers measure baseline C3, C4, and sometimes more specialized complement factors. For trials testing complement inhibitors, low complement levels may be required for entry, and serial measurements track whether the drug successfully modulates complement activity.^[5]

Additional tests depend on the trial’s focus. Studies investigating immunosuppressive treatments often require complete blood counts and liver function tests to ensure patients can safely tolerate the medication. Researchers may test for specific antibodies or genetic markers that predict treatment response. Some trials exclude patients with active infections or certain underlying conditions that could confound results or pose safety risks.^[7]

Monitoring during clinical trials involves repeated diagnostic tests at specified intervals. Patients typically provide urine samples and blood samples at each visit. Kidney biopsies may be repeated to assess whether the experimental treatment reduces inflammation or deposits in kidney tissue. Imaging studies and other specialized tests track both beneficial effects and potential side effects of the treatment under investigation.^[7]